Ipsen, GlaxoSmithKline and Johnson & Johnson join consortium for UK-based biotech company Syntaxin.
Syntaxin, a UK-based biotech company for pain relief, has raised £18m ($29m) in its series C round from a consortium including multiple corporate venturing units.
Healthcare companies Ipsen, GlaxoSmithKline (GSK) and Johnson & Johnson were the corporate venturing units. Lundbeckfond Ventures, an open and evergreen life science venture fund managed by the asset management subsidiary of Denmark’s Lundbeck Foundation, and venture capital (VC) firms Abingworth, Life Sciences Partners (LSP), Seventure Partners and Quest For Growth made up the rest…
